Status:
UNKNOWN
Tenecteplase Thrombolytic Therapy for Acute Ischemic Stroke in China
Lead Sponsor:
Huashan Hospital
Collaborating Sponsors:
Keshiketeng Banner Traditional Chinese Medicine Mongolian Medicine Hospitalorem Ipsum
Nanshi Hospital of Nanyang
Conditions:
Ischemic Stroke
Eligibility:
All Genders
Brief Summary
The objective of the study is to investigate the effectiveness and safety of rhTNK-tPA in acute ischemic stroke patients within 4.5 hours of symptom onset in a real-world clinical setting.
Detailed Description
Recombinant human tenecteplase tissue-type plasminogen activator (rhTNK-tPA) has the logistic advantage of a single bolus infusion over recombinant tissue plasminogen activator (rt-PA) which needs a 1...
Eligibility Criteria
Inclusion
- all acute ischaemic stroke patients who met eligibility for thrombolysis with intravenous alteplase or TNK and presenting within 4·5 hours of symptom onset.
Exclusion
- variables with a missing rate \> 40%
Key Trial Info
Start Date :
April 2 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2024
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT06078995
Start Date
April 2 2023
End Date
May 1 2024
Last Update
October 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xin Chen
Shanghai, China